The University of Chicago Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Gordon, Kenneth
One or more keywords matched the following items that are connected to Gordon, Kenneth
Item TypeName
Concept Severity of Illness Index
Academic Article Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
Academic Article Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.
Academic Article A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
Academic Article Duration of remission of biologic agents for chronic plaque psoriasis.
Academic Article Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.
Academic Article The editor's roundtable: psoriasis, inflammation, and coronary artery disease.
Academic Article From laboratory to clinic: rationale for biologic therapy.
Academic Article Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis.
Academic Article Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
Academic Article Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.
Academic Article Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
Academic Article Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
Academic Article An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.
Academic Article Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.
Academic Article Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
Academic Article Evolution of biologic therapies for the treatment of psoriasis.
Academic Article Remittive effects of intramuscular alefacept in psoriasis.
Academic Article Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.
Academic Article Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
Academic Article Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.
Academic Article Unmet needs in the treatment of psoriasis.
Academic Article A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
Academic Article Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Academic Article A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
Academic Article Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials.
Academic Article Clinical meaningfulness of complete skin clearance in psoriasis.
Academic Article Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Academic Article The experience of pain and redness in patients with moderate to severe plaque psoriasis.
Academic Article Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
Academic Article Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption.
Academic Article Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Academic Article The inpatient burden of psoriasis in the United States.
Academic Article Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity.
Academic Article Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
Academic Article Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity.
Academic Article Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis.
Academic Article Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis.
Academic Article Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
Academic Article Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory.
Academic Article Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Academic Article Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Academic Article Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis.
Academic Article Treating to Target-A Realistic Goal in Psoriasis?
Academic Article The Evolving Landscape of Psoriasis Treatment.
Academic Article Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
Academic Article Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Academic Article Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis.
Academic Article Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis.
Academic Article Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials.
Academic Article Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
Academic Article Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis.
Academic Article Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis.
Academic Article Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Academic Article Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.
Academic Article Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study.
Academic Article Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis.
Academic Article Risankizumab in moderate-to-severe plaque psoriasis.
Academic Article Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
Academic Article A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Academic Article Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry.
Academic Article Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies.
Academic Article Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials.
Academic Article Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2).
Academic Article Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.
Academic Article Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study.
Academic Article Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.
Academic Article Efficacy, safety, usability, and acceptability of risankizumab 150?mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis.
Academic Article Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.
Academic Article Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.
Academic Article Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.
Academic Article Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
Academic Article Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.
Academic Article Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.
Academic Article Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial.
Academic Article Bimekizumab for the treatment of psoriasis.
Search Criteria
  • Severity of Illness Index